Detalhe da pesquisa
1.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol
; 16(13): 1355-69, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26361971
2.
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Eur J Cancer
; 101: 105-113, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30036739